CU-CPT17e

CAS No. 2109805-75-4

CU-CPT17e( —— )

Catalog No. M23960 CAS No. 2109805-75-4

CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 419 In Stock
10MG 617 In Stock
25MG 938 In Stock
50MG 1293 In Stock
100MG 1739 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CU-CPT17e
  • Note
    Research use only, not for human use.
  • Brief Description
    CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).
  • Description
    CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    TLR
  • Recptor
    TLR3|TLR8|TLR9
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2109805-75-4
  • Formula Weight
    504.49
  • Molecular Formula
    C27H24N2O8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM (Need ultrasonic and warming)
  • SMILES
    O=[N+]([O-])C(C=C1)=CC=C1COC2=CC(C=CC3(CCOCC3)O4)=C4C=C2OCC5=CC=C([N+]([O-])=O)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhang L, et al. Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities. J Med Chem. 2017 Jun 22;60(12):5029-5044.
molnova catalog
related products
  • CU-CPT-9a

    CU-CPT-9a is a potent TLR8 inhibitor (IC50 : 0.5 nM) that suppresses TLR8-mediated proinflammatory signaling in various cell lines.

  • ABR-238901

    ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).

  • AXC-715 trihydrochlo...

    AXC-715 trihydrochloride (T785 trihydrochloride) is a TLR7/TLR8 dual agonist for the synthesis of antibody-adjuvanted immunocouplings.